Vergelijking
Efinopegdutide vs. Glucagon
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Metabool
Metabool
CAS-nr.
2055640-93-0
16941-32-5
Molecuulmassa
geen gegevens
3483 g/mol
Halfwaardetijd
115 h
0.13 h
Sequentie
modifiziertes, von Oxyntomodulin abgeleitetes Peptid, konjugiert an ein humanes IgG4-Fragment (Verlängerung der Plasma-Halbwertszeit)HSQGTFTSDYSKYLDSRRAQDFVQWLMNTWerkingsmechanisme
Efinopegdutide
Efinopegdutide is an oxyntomodulin-derived peptide acting as a dual agonist at the GLP-1 and glucagon receptors with a relative potency of approximately 2:1 (GLP-1 to glucagon). The GLP-1 component mediates glucose-dependent insulin secretion and modulation of satiety; the glucagon component increases energy expenditure and hepatic fat oxidation, which is proposed to contribute to the observed reduction in liver fat. Conjugation to an IgG4 fragment prolongs the half-life and enables weekly administration.
Glucagon
Glucagon is produced in the alpha cells of the pancreas (islets of Langerhans) and released when blood sugar is low. Glucagon binds the glucagon receptor (GCGR), a G-protein-coupled receptor expressed predominantly on hepatocytes. Activation stimulates adenylate cyclase, raises cyclic AMP and activates protein kinase A. This drives glycogenolysis (breakdown of hepatic glycogen into glucose) and gluconeogenesis (de novo glucose synthesis), which raises blood glucose. Glucagon also promotes lipolysis. As the counterpart to insulin it contributes to glucose homeostasis. It transiently relaxes gastrointestinal smooth muscle, which is the basis of its diagnostic use in imaging.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane RCT
Studies
3
4
waarvan bij mensen
3
4
Geregistreerde effecten
4
4
Openstaande tegenstrijdigheden
1
1
Gedocumenteerde bijwerkingen
1
1
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between Efinopegdutide and Glucagon?
- Efinopegdutide is classified as "Metabool", while Glucagon is classified as "Metabool". Efinopegdutide: Efinopegdutide (MK-6024, formerly JNJ-64565111 / HM12525A) is a once-weekly dual agonist at the GLP-1 and glucagon receptors, developed by Hanmi and Merck. It has been studied for obesity and notably for metabolic liver disease (MASH/NAFLD); a phase-2 trial showed greater liver-fat reduction than semaglutide. Investigational, not approved. Glucagon: Glucagon is a 29-amino-acid pancreatic hormone produced by the alpha cells of the islets of Langerhans. It is the physiological counterpart to insulin and raises blood glucose via hepatic glycogenolysis and gluconeogenesis. It is approved as an emergency treatment for severe hypoglycaemia and as a diagnostic aid; its receptor is also a target of modern dual and triple incretin agonists. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Efinopegdutide or Glucagon?
- The highest available evidence level is "Humane RCT" for Efinopegdutide and "Humane RCT" for Glucagon. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Efinopegdutide and Glucagon in Germany and the United States?
- Duitsland: Efinopegdutide — Niet goedgekeurd, Glucagon — Op recept. Verenigde Staten: Efinopegdutide — Niet goedgekeurd, Glucagon — Op recept. These are factual summaries with source and review date on the individual pages.